Company intelligence / Profile preview
DanausGT Biotechnology
Suzhou, Chinadanausgt.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DanausGT has multiple pipelines from preclinical to Phase 1, including CG001 for pyruvate kinase deficiency (EMA orphan drug designation, IND expected mid-2023) and others with orphan drug status; focuses on precise gene replacement with high efficiency and no off-target effects.
- Therapeutic areas
- HematologyNeurologyDermatologyGastroenterologyOncology
- Modalities
- Gene therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Porton Advanced Solutions Ltd.
Beyond the preview
Go deeper on DanausGT Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DanausGT Biotechnology.